VILOXAZINE

Details

Stereochemistry	RACEMIC
Molecular Formula	C13H19NO3
Molecular Weight	237.2954
Optical Activity	( + / - )
Defined Stereocenters	0 / 1
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

CCOc1ccccc1OCC2CNCCO2

InChI

InChIKey=YWPHCCPCQOJSGZ-UHFFFAOYSA-N

InChI=1S/C13H19NO3/c1-2-15-12-5-3-4-6-13(12)17-10-11-9-14-7-8-16-11/h3-6,11,14H,2,7-10H2,1H3

HIDE SMILES / InChI

Molecular Formula	C13H19NO3
Molecular Weight	237.2954
Charge	0
Count

Stereochemistry	RACEMIC
Additional Stereochemistry	No
Defined Stereocenters	0 / 1
E/Z Centers	0
Optical Activity	( + / - )

Description
Sources: https://www.ncbi.nlm.nih.gov/pubmed/22454923 | https://www.ncbi.nlm.nih.gov/pubmed/324751 | http://bipolarnews.org/?tag=viloxazine | https://www.ncbi.nlm.nih.gov/pubmed/30924702

Viloxazine is an antidepressant drug was used to treat patients with depression. Viloxazine inhibits noradrenaline uptake. This drug was approved in some Europe countries, but not in the USA, but then it was discontinued because of competition from other drugs. In the frame of drug repositioning, Viloxazine participated in clinical trials for the treatment of attention deficit hyperactivity disorder. Phase II of trials was successfully passed.

Approval Year

Targets

Primary Target	Pharmacology	Condition	Potency
Sodium-dependent noradrenaline transporter 38 Target ID: P23975 Gene ID: 6530.0 Gene Symbol: SLC6A2 Target Organism: Homo sapiens (Human) Sources: https://www.ncbi.nlm.nih.gov/pubmed/27230580	Inhibitor 7687
Sodium-dependent noradrenaline transporter 38 Target ID: P23975 Gene ID: 6530.0 Gene Symbol: SLC6A2 Target Organism: Homo sapiens (Human) Sources: https://www.ncbi.nlm.nih.gov/pubmed/27230580	Inhibitor 7687

PubMed

Title	Date	PubMed
Contribution of sleep research to the development of new antidepressants.	2005	16416706
The AGNP-TDM Expert Group Consensus Guidelines: focus on therapeutic monitoring of antidepressants.	2005	16156382
Gastrointestinal bleeding and massive liver damage in neuroleptic malignant syndrome.	2005 Sep	18360563
[Trazodone for the treatment of behavioral and psychological symptoms of dementia (BPSD) in Alzheimer's disease: a retrospective study focused on the aggression and negativism in caregiving situations].	2006 Jun	16856516
Quantitative determination of forty-eight antidepressants and antipsychotics in human serum by HPLC tandem mass spectrometry: a multi-level, single-sample approach.	2006 Oct 20	16798119
Comparison of electron and chemical ionization modes by validation of a quantitative gas chromatographic-mass spectrometric assay of new generation antidepressants and their active metabolites in plasma.	2007 Dec 28	18022628
Quantification of tricyclic antidepressants and monoamine oxidase inhibitors by high-performance liquid chromatography-tandem mass spectrometry in whole blood.	2007 May	17555643
Antidepressant drugs for narcolepsy.	2008 Jan 23	18254030
Narcolepsy: current treatment options and future approaches.	2008 Jun	18830438
Adjustment Disorder: epidemiology, diagnosis and treatment.	2009 Jun 26	19558652
Determination of antidepressants in human postmortem blood, brain tissue, and hair using gas chromatography-mass spectrometry.	2009 Nov	18839201

Patents

Sample Use Guides

In Vivo Use Guide

100 mg

Route of Administration: Oral

Substance Class	Chemical Created by `admin` on `Fri Jun 25 23:08:57 UTC 2021` Edited by `admin` on `Fri Jun 25 23:08:57 UTC 2021`
Record UNII	5I5Y2789ZF
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

VILOXAZINE

Official Name

English

VILOXAZINE [INN]

Common Name

English

VILOXAZINE [WHO-DD]

Common Name

English

VILOXAZINE [MI]

Common Name

English

MORPHOLINE, 2-((2-ETHOXYPHENOXY)METHYL)-

Systematic Name

English

(+/-)-2-(O-ETHOXYPHENOXYMETHYL)MORPHOLINE

Common Name

English

VILOXAZIN

Common Name

English

VILOXAZINE [VANDF]

Common Name

English

Classification Tree Code System Code

WHO-ATC

N06AX09